Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin

NCT02620280 is registered in ClinicalTrials.gov with Fondazione Michelangelo as lead sponsor.

NCT NCT02620280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02620280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin
Lead sponsor
Fondazione Michelangelo
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2016
Completion date
January 7, 2024
Enrollment
278 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

invasive ductal breast carcinoma